Immunotherapy marks a paradigm shift in our approach to treating a myriad of conditions, particularly cancer. By leveraging the body's defense mechanisms, immunotherapy offers a personalized and often less invasive alternative to traditional treatments such as chemotherapy and radiation.
Central to the success of this approach is the use of advanced diagnostic tools, among which flow cytometry is pivotal. This technology is instrumental in designing and monitoring immunotherapies through cell profiling, cell sorting, functional assays, and drug screening. High-throughput screening (HTS) by flow cytometry enables the rapid analysis of a large number of cells, allowing for the identification and characterization of cellular responses.
In this panel, we will delve into the critical role of HTS, in the research and development of immunotherapies. We will highlight the value of HTS to researchers and discuss the advancements necessary to propel immunotherapies forward.
Attend this panel to: